Thomas Schäfer Executive Vice President & Chief Scientific Officer, and member of the Executive Board will step down as EVP and CSO of Chr. Hansen Holding A/S effective March 31, 2022. Thomas Schäfer has been with the company since November 2017.
Since Thomas started in Chr. Hansen four and a half years ago, he has brought significant scientific knowledge to the company and strengthened the way Chr. Hansen approaches science. We continue to move forward with our strong science platform and our journey of a customer centric and agile innovation organization.
As of April 1, 2022, Henrik Joerck Nielsen, currently Senior Vice President Animal Health, will be promoted to Chief Scientific Officer. Henrik has a Ph.D. in Biotechnology from the Technical University of Denmark and National Institute of Health in Maryland. He did his post-doctoral research fellow at the National Cancer Institute in the US (2006-2008). After being with McKinsey six years, he joined Chr. Hansen in 2014. Henrik brings a strong science and commercial experience to his new role.
Thomas Schäfer will continue as Chief Science Advisor to CEO Mauricio Graber, as well as continue as member of the Board of Directors in Bacthera AG (Chr. Hansen’s Joint Venture with Lonza AG) and the BioInnovation Institute.”
Mauricio Graber, CEO of Chr. Hansen, said: “I would like to thank Thomas for his contribution to Chr. Hansen and I look forward to continuing working with Thomas in his new role as Chief Science Advisor. At the same time, I would like to congratulate Henrik on his new position as Chief Scientific Officer, as we embark on the next journey as a bioscience-based company.”
Following the change, the Executive Board will consist of CEO Mauricio Graber and CFO Lise Mortensen. The Executive Board is appointed by the Board of Directors and is responsible for the day-to-day management of the company within the guidelines and directions given by the Board of Directors.
For further information please contact:
Anders Mohr Christensen, Vice President Group Strategy & Investor Relations, Tel: +45 2515 2364
Annika Stern, Senior Investor Relations Manager, Tel: +45 2399 2382
Sanne Seyer-Hansen, Head of Media Relations, Tel: +45 6038 6207
科 汉森是一家全球性且具备差异化的生物科技公司，为食品行业、营养行业、制药行业和畜牧业开发天然原料的解决方案。 在科 汉森，我们拥有独特的优势，可通过微生物解决方案推动积极的变革。 在过去超过 145 年的时间里，我们致力于实现可持续的农业、更好的食品以及让全世界更多的人过上更健康的生活。 我们的微生物和发酵技术平台拥有改变规则的潜力，库存广泛且价值重大，包括约 40,000 种微生物菌株。 除了适应客户需求和全球趋势外，我们还将挖掘释放有益菌的力量，以应对食物浪费、全球健康以及抗生素和杀虫剂滥用等全球挑战。 作为全世界最具可持续性的生物技术公司，我们每天影响超过 10 亿人的生活。 受我们的创新传统与对前沿科学的求知驱动，公司宗旨“To grow a better world. Naturally.”体现在我们的所有工作中。